ECSP067020A - Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica - Google Patents

Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica

Info

Publication number
ECSP067020A
ECSP067020A EC2006007020A ECSP067020A ECSP067020A EC SP067020 A ECSP067020 A EC SP067020A EC 2006007020 A EC2006007020 A EC 2006007020A EC SP067020 A ECSP067020 A EC SP067020A EC SP067020 A ECSP067020 A EC SP067020A
Authority
EC
Ecuador
Prior art keywords
group
alkyl
optionally substituted
hydrogen atom
alkylidene
Prior art date
Application number
EC2006007020A
Other languages
English (en)
Spanish (es)
Inventor
Martin Juan Antonio Diaz
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34944870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067020(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP067020A publication Critical patent/ECSP067020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EC2006007020A 2004-05-25 2006-11-22 Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica ECSP067020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405607A FR2870846B1 (fr) 2004-05-25 2004-05-25 Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
PCT/FR2005/001279 WO2005118547A1 (fr) 2004-05-25 2005-05-24 Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
ECSP067020A true ECSP067020A (es) 2006-12-29

Family

ID=34944870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007020A ECSP067020A (es) 2004-05-25 2006-11-22 Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica

Country Status (41)

Country Link
US (3) US7833999B2 (ru)
EP (1) EP1753725B1 (ru)
JP (1) JP4861979B2 (ru)
KR (1) KR101176675B1 (ru)
CN (1) CN1956962B (ru)
AR (1) AR050250A1 (ru)
AU (1) AU2005250197B2 (ru)
BR (1) BRPI0511581A (ru)
CA (1) CA2565293C (ru)
CR (1) CR8735A (ru)
CY (1) CY1114240T1 (ru)
DK (1) DK1753725T3 (ru)
DO (1) DOP2005000103A (ru)
EA (1) EA010234B1 (ru)
EC (1) ECSP067020A (ru)
ES (1) ES2407140T3 (ru)
FR (1) FR2870846B1 (ru)
GT (1) GT200500126A (ru)
HK (1) HK1106229A1 (ru)
HN (1) HN2005000239A (ru)
HR (1) HRP20130431T1 (ru)
IL (1) IL179021A (ru)
JO (1) JO2877B1 (ru)
MA (1) MA28720B1 (ru)
MX (1) MXPA06013629A (ru)
MY (1) MY148980A (ru)
NI (1) NI200600279A (ru)
NO (1) NO338104B1 (ru)
NZ (1) NZ551509A (ru)
PA (1) PA8634501A1 (ru)
PE (1) PE20060273A1 (ru)
PL (1) PL1753725T3 (ru)
PT (1) PT1753725E (ru)
SI (1) SI1753725T1 (ru)
SV (1) SV2006002126A (ru)
TN (1) TNSN06356A1 (ru)
TW (1) TWI360540B (ru)
UA (1) UA84771C2 (ru)
UY (1) UY28917A1 (ru)
WO (1) WO2005118547A1 (ru)
ZA (1) ZA200609820B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664245B2 (en) 2009-06-26 2014-03-04 Sanofi Fumarate salts of a histamine H3 receptor antagonist

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PL2221298T3 (pl) 2007-11-13 2014-05-30 Taisho Pharmaceutical Co Ltd Pochodne fenylopirazolu
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
TWI555741B (zh) 2011-12-08 2016-11-01 大正製藥股份有限公司 Phenylpyrrole derivatives
EP2799436A4 (en) 2011-12-27 2015-07-01 Taisho Pharmaceutical Co Ltd PHENYLTRIAZOLDERIVAT
EP2647377A1 (en) * 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN110642854A (zh) * 2019-11-20 2020-01-03 成都克莱蒙医药科技有限公司 一种稠环化合物的多晶型、其组合物、制备方法及其应用
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
AU709611B2 (en) * 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
EP1070714B1 (en) 1998-04-10 2004-08-04 Japan Tobacco Inc. Amidine compounds
JP2003500382A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
ES2241891T3 (es) 2001-01-02 2005-11-01 F. Hoffmann-La Roche Ag Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
EP1461311A2 (en) * 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
JP2003192660A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
US7220306B2 (en) 2002-03-08 2007-05-22 Sakata Ink Corp. Treated pigment, use thereof, and compound for treating pigment
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US20040097574A1 (en) * 2002-08-29 2004-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ZA200603515B (en) 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1630159A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
US20080261999A1 (en) 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664245B2 (en) 2009-06-26 2014-03-04 Sanofi Fumarate salts of a histamine H3 receptor antagonist

Also Published As

Publication number Publication date
FR2870846A1 (fr) 2005-12-02
TNSN06356A1 (en) 2008-02-22
HN2005000239A (es) 2009-04-27
US7833999B2 (en) 2010-11-16
PT1753725E (pt) 2013-05-21
SI1753725T1 (sl) 2013-06-28
ES2407140T3 (es) 2013-06-11
PL1753725T3 (pl) 2013-07-31
US20120323003A1 (en) 2012-12-20
PE20060273A1 (es) 2006-04-22
AU2005250197B2 (en) 2010-09-23
IL179021A (en) 2012-04-30
NO20065918L (no) 2006-12-19
US8524700B2 (en) 2013-09-03
EA010234B1 (ru) 2008-06-30
DOP2005000103A (es) 2006-02-15
CN1956962B (zh) 2014-08-20
NO338104B1 (no) 2016-08-01
PA8634501A1 (es) 2006-05-16
EP1753725A1 (fr) 2007-02-21
US20110028475A1 (en) 2011-02-03
CA2565293A1 (fr) 2005-12-15
MA28720B1 (fr) 2007-07-02
IL179021A0 (en) 2007-03-08
US20070105834A1 (en) 2007-05-10
WO2005118547A1 (fr) 2005-12-15
GT200500126A (es) 2006-02-17
CA2565293C (fr) 2012-10-30
NZ551509A (en) 2009-12-24
UY28917A1 (es) 2005-12-30
TWI360540B (en) 2012-03-21
HK1106229A1 (en) 2008-03-07
JP2008500313A (ja) 2008-01-10
TW200609220A (en) 2006-03-16
HRP20130431T1 (en) 2013-06-30
KR101176675B1 (ko) 2012-08-23
CR8735A (es) 2007-08-28
BRPI0511581A (pt) 2008-01-02
NI200600279A (es) 2008-01-22
EP1753725B1 (fr) 2013-02-27
KR20070021223A (ko) 2007-02-22
DK1753725T3 (da) 2013-05-27
UA84771C2 (ru) 2008-11-25
SV2006002126A (es) 2006-01-13
CY1114240T1 (el) 2016-08-31
ZA200609820B (en) 2008-06-25
AU2005250197A1 (en) 2005-12-15
CN1956962A (zh) 2007-05-02
JO2877B1 (en) 2015-03-15
EA200602176A1 (ru) 2007-04-27
FR2870846B1 (fr) 2006-08-04
AR050250A1 (es) 2006-10-11
JP4861979B2 (ja) 2012-01-25
MXPA06013629A (es) 2007-03-23
MY148980A (en) 2013-06-28
US8273733B2 (en) 2012-09-25

Similar Documents

Publication Publication Date Title
ECSP067020A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
ES2590504T3 (es) N-ciclilamidas como nematicidas
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR049291A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ES2247527T3 (es) Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
CO6260018A2 (es) Combinaciones de principios activos que contienen derivados de acido tetramico sustituidos con espirocetales
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
CO5650253A2 (es) Piperazina con grupo fenilo or-sustituido y su uso como inhibidores de glyt1
CO6251247A2 (es) Imidazoquinolinas con propiedades inmuno-moduladoras
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
AR050266A1 (es) Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa
AR052450A1 (es) Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica
AR112274A1 (es) Compuestos bicíclicos de cetona y sus métodos de uso
MX2016004960A (es) Estabilizadores de luz de amina bloqueada a base de triazina, piperidina y pirrolidina.
AR109991A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
ECSP088257A (es) Derivados de amida
AR055666A1 (es) Inhibidores inntr
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
DOP2006000253A (es) Derivados de isoquinolina y benzo[h]isoquinolina, su preparación y su utilización en terapéutica